Electromed, Inc.

As of September 12, 2025, Electromed, Inc. shows a neutral trend with mixed technical indicators, having outperformed the S&P 500 over the past year but underperformed year-to-date, suggesting a cautious outlook.

As of August 26, 2025, Electromed, Inc. is fairly valued with a P/E ratio of 25 and an EV to EBITDA of 16.14, indicating it is priced at a premium compared to some peers, despite its previous attractive rating.

As of February 19, 2025, Electromed, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 25, an EV to EBITDA of 16.14, a PEG ratio of 0.38, a strong ROCE of 31.20%, and a 48.39% return over the past year, outperforming the S&P 500.

As of May 5, 2025, the technical trend has shifted to mildly bearish due to bearish signals from the MACD, moving averages, and Bollinger Bands, despite a bullish weekly RSI.

As of March 2022, the management team of Electromed, Inc. includes Independent Chairman Mr. Stephen Craney, President and CEO Ms. Kathleen Skarvan, and several Independent Directors: Mr. Stan Erickson, Mr. Gregory Fluet, Ms. Lee Jones, Ms. Andrea Walsh, and Dr. George Winn. They oversee the company's strategic direction and governance.

Electromed, Inc. develops and markets airway clearance products using High Frequency Chest Wall Oscillation therapy, with recent net sales of $16 million and a market cap of $168.31 million. The company operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.

As of Jun 18, Electromed, Inc. has a market capitalization of 168.31 million and reported net sales of 61.43 million with a net profit of 7.16 million over the last four quarters.